sideroblast


Also found in: Dictionary, Medical, Wikipedia.
Related to sideroblast: Myelodysplastic syndrome, ferritin
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to sideroblast

an erythroblast having granules of ferritin

Related Words

References in periodicals archive ?
Of the nine cases of myelodysplastic syndrome four were refractory anemia, two were refractory cytopenia with multilineage dysplasia, one was refractory Anemia with Ring sideroblast and two cases of refractory Anemia with excess blasts which compares with the similar study conducted in India 4.
The myelodysplastic syndromes are characterised by refractory anaemia and ringed sideroblasts, which can transform into a state with excess blasts and then on to acute leukaemia.
Some of the recent data indicate defective heme synthesis, [13], which would explain the ring sideroblasts, but the mechanism in undefined.
These changes include myeloid hyperplasia and increased iron stores with decreased siderocytes and sideroblasts.
An appropriate iron stain is needed to demonstrate the distinctive and diagnostically important ringed sideroblasts (Fig.
Patients with mutations in the SF3B1 gene frequently had a specific abnormality of red blood cells in their bone marrow, called ring sideroblasts, researchers said.
The peripheral smear of patients typically includes two distinct erythrocyte populations: normochromic normocytic erythrocytes together with hypochromic microcytic cells Bone marrow examination reveals ringed sideroblasts due to increased iron within mitochondrial ferritin (57).
der(4)t(1;4)(q21;q35) +mar, t(7;13), t(8;21) (q22;q22), t(1;X)(p21;q31),-7 in refractory anaemia with excessive blasts transformation (RAEB-t), del(2)(q33-ter) in chronic myelomonocytic leukemia (CMMOL) and trisomy 14 in refractory anaemia with ring sideroblasts (RARS).
26) (A sideroblastic anemia is marked by large numbers of ringed sideroblasts in the bone marrow, ineffective production of red blood cells, hypochromic erythrocytes in the peripheral blood, and, usually, increased levels of tissue iron.
S Food and Drug Administration (FDA) on May 2, 2006 for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.
classification [1], five patients had refractory anaemia (RA) and one patient had refractory anaemia with ring sideroblasts (RARS).
VIDAZA is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
This trial is a randomized, double-blind, placebo-controlled, global study designed to evaluate the efficacy and safety of luspatercept in patients with ring sideroblasts, lower-risk MDS with a baseline RBC transfusion burden of at least 2 units per 8 weeks over the 16-week period prior to treatment.
14) The presence of both SF3B1 and JAK2 mutations is diagnostic and prognostic for refractory anemia with ring sideroblasts with thrombocytosis, (15) now classified as a specific subtype of MDS/MPN.